{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:29:36Z","timestamp":1793788176190,"version":"4.6.1"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.eclinm.2026.104258","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:49:04Z","timestamp":1791830944000},"page":"104258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Relative risk reduction is not enough: why cardiorenal trials should routinely report absolute risk reduction and number needed to treat"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4979-3799","authenticated-orcid":false,"given":"Hussein","family":"Zaitoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Abdul-Ghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3839-1724","authenticated-orcid":false,"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.104258_bib1","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jclinepi.2013.01.011","article-title":"Absolute risks rather than incidence rates should be used to estimate the number needed to treat from time-to-event data","volume":"66","author":"Bender","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2026.104258_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104258_bib3","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-Positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104258_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104258_bib5","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104258_bib6","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.104258_bib7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104258_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104258_bib9","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104258_bib10","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104258_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/kidneydial5030038","article-title":"Truth and pitfalls of evidence-based medicine","volume":"5","author":"Campese","year":"2025","journal-title":"Kidney Dial"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104258_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/kidneydial5040058","article-title":"Caution in interpreting number needed to treat and number needed to harm in clinical trials","volume":"5","author":"Tripepi","year":"2025","journal-title":"Kidney Dial"},{"key":"10.1016\/j.eclinm.2026.104258_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/kidneydial6020027","article-title":"Beyond relative risk: a methodological framework for interpreting measures of effect and improving data presentation in randomized controlled trials (RCTs)","volume":"6","author":"Tripepi","year":"2026","journal-title":"Kidney Dial"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026005110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026005110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:05:38Z","timestamp":1793786738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026005110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":13,"alternative-id":["S2589537026005110"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104258","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relative risk reduction is not enough: why cardiorenal trials should routinely report absolute risk reduction and number needed to treat","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104258"}}